Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies

Metabolic-associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of M...

Full description

Saved in:
Bibliographic Details
Main Authors: John Cooper, Parth Patel, Joven Tristeza, Alexander Yang
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:International Journal of Hepatology
Online Access:http://dx.doi.org/10.1155/ijh/5580454
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849424511484559360
author John Cooper
Parth Patel
Joven Tristeza
Alexander Yang
author_facet John Cooper
Parth Patel
Joven Tristeza
Alexander Yang
author_sort John Cooper
collection DOAJ
description Metabolic-associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of MASLD are still being elucidated. In this review, we will summarize the known molecular mechanisms in the development of MASLD along with past, current, and future pharmacologic clinical trials.
format Article
id doaj-art-478d1ab6fbf44dca87ef937453776259
institution Kabale University
issn 2090-3456
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series International Journal of Hepatology
spelling doaj-art-478d1ab6fbf44dca87ef9374537762592025-08-20T03:30:08ZengWileyInternational Journal of Hepatology2090-34562025-01-01202510.1155/ijh/5580454Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel TherapiesJohn Cooper0Parth Patel1Joven Tristeza2Alexander Yang3Internal MedicineInternal MedicineInternal MedicineInternal MedicineMetabolic-associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of MASLD are still being elucidated. In this review, we will summarize the known molecular mechanisms in the development of MASLD along with past, current, and future pharmacologic clinical trials.http://dx.doi.org/10.1155/ijh/5580454
spellingShingle John Cooper
Parth Patel
Joven Tristeza
Alexander Yang
Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
International Journal of Hepatology
title Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
title_full Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
title_fullStr Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
title_full_unstemmed Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
title_short Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
title_sort metabolic associated steatotic liver disease from molecular mechanisms to novel therapies
url http://dx.doi.org/10.1155/ijh/5580454
work_keys_str_mv AT johncooper metabolicassociatedsteatoticliverdiseasefrommolecularmechanismstonoveltherapies
AT parthpatel metabolicassociatedsteatoticliverdiseasefrommolecularmechanismstonoveltherapies
AT joventristeza metabolicassociatedsteatoticliverdiseasefrommolecularmechanismstonoveltherapies
AT alexanderyang metabolicassociatedsteatoticliverdiseasefrommolecularmechanismstonoveltherapies